

Dissemination of multiple carbapenem resistance genes in an in-vitro gut model simulating the human colon.

*Rooney CM^{1,2}, Sheppard AE^{3,4}, Clark E², Davies K^{1,2}, Hubbard ATM³, Sebra R⁵, DW Crook^{3,4}, Walker AS^{3,4}, Wilcox MH^{1,2}, Chilton C².

1. Leeds Teaching Hospitals NHS Trust, Department of Microbiology, Old Medical School, Thoresby Place, Leeds, UK.
2. University of Leeds, Healthcare Associated Infection Research Group Department of Microbiology, Old Medical School, Thoresby Place, Leeds, UK.
3. Nuffield Department of Medicine, University of Oxford, Henry Wellcome Building for Molecular Physiology, Old Road Campus, Headington, Oxford, UK.
4. NIHR Health Protection Unit in Healthcare Associated Infections and Antimicrobial Resistance at University of Oxford in partnership with Public Health England, Oxford, UK;
5. Icahn Institute and Department of Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029-6574. USA.

*Corresponding author: christopherrooney@nhs.net, Tel 0113 3926818, Fax 0113 3922696.

Running title: Carbapenem gene dissemination in gut microbiota

Abstract

Background

Carbapenemase-producing Enterobacteriaceae (CPE) pose a major global health risk. Mobile genetic elements account for much of the increasing CPE burden.

Objective

To investigate CPE colonisation and the impact of antibiotic exposure on subsequent resistance gene dissemination within the gut microbiota using a model to simulate the human colon.

Methods

Gut models seeded with CPE-negative human faeces (screened with BioMerieux chromID® CARBA SMART (Carba-Smart), Cepheid Xpert® Carba-R assay (XCR)) were inoculated with distinct carbapenemase-producing *Klebsiella pneumoniae* strains (KPC, NDM) and challenged with imipenem or piperacillin/tazobactam, meropenem. Resistant populations were enumerated daily on selective agars (Carba-Smart); CPE genes were confirmed by PCR (XCR, Check-Direct CPE Screen for BD MAX™ (CDCPE)). CPE gene dissemination was tracked using PacBio® long-read sequencing.

Results

CPE populations increased during inoculation, plateauing at $\sim 10^5$ log₁₀cfu/mL in both models and persisting throughout the experiments (>65 days), with no evidence of CPE ‘washout’. Post-antibiotic administration, there was evidence of interspecies plasmid transfer of blaKPC-2 (111,742bp IncFII/IncR plasmid, 99% identity to pKpQIL-D2) and blaNDM-1 (~200kb IncFIB/IncFII plasmid), and CPE populations rose from <0.01% to >45% of the total lactose-fermenting populations in the KPC model. Isolation of a blaNDM-1 *K. pneumoniae* isolate with one chromosomal single nucleotide variant versus the inoculated strain indicated clonal expansion within the model. Antibiotic administration exposed a previously undetected *K. pneumoniae* encoding blaOXA-232 (KPC model).

Conclusions

CPE exposure can lead to colonisation, clonal expansion and resistance gene transfer within intact human colonic microbiota. Furthermore, under antibiotic selective pressure, new resistant

populations emerge, emphasising the need for antimicrobial-exposure control.

Introduction

Carbapenemase producing Enterobacteriaceae (CPE) pose a major global health risk, with reports of outbreaks of CPE throughout Europe¹ including the United Kingdom (UK),^{2,3} most notably in the North-West of England, where a large outbreak has contributed to national spread.^{4,5} Factors driving CPE acquisition and subsequent gene dissemination include increasing age,⁴ antibiotic therapy,^{4,6-8} presence of intravascular access device/invasive procedure,^{6,8,9} prolonged hospital stay,^{6,7,9} multiple co-morbidities⁸ and proximity to the index case.^{6,7} Such reports identify potential 'at risk' individuals, but do not fully explain why some outbreaks can be contained with infection control measures,¹⁰⁻¹² while others are not.^{13,14} Unlike nosocomial outbreaks of *Clostridium difficile* or methicillin-resistant *Staphylococcus aureus*, CPE outbreaks often involve multiple bacterial species and multiple resistance genes carried on mobile genetic elements^{12,15,16}.

The epidemiology of carbapenem resistance and specifically the genes encoding carbapenemases is complex.^{17,18} For example, while much of the global spread of CPE is due to *K. pneumoniae* harbouring KPC resistance genes,^{3,19,20} clonal populations of *K. pneumoniae* encoding VIM genes in Greece,²¹ outbreaks of OXA-48 in Turkey and the UK,^{22,23} and the higher prevalence of IMP resistance genes in southern Europe and Asia,²⁴ demonstrate the heterogeneous epidemiology. This implies that there are factors beyond bacterial species or single exposure events that potentiate or limit the spread of specific carbapenem resistance genes.

Susceptible bacterial populations gain resistance through mutation or via horizontal gene transfer of mobile genetic elements. The human large intestine is the ideal setting for resistance gene transfer, largely due to its high biomass. Here we have used an *in-vitro* human gut model, that has previously successfully simulated the colon in the context of *C. difficile* infection,²⁵⁻²⁷ to assess the factors favouring the dissemination of carbapenem resistance genes, and used long-read single molecule real-time (SMRT) sequencing to further understand CPE resistance gene dissemination.

Methods

In-Vitro human gut model

Two triple stage human gut models were used, as previously described²⁶. Briefly, the model consists of a triple stage chemostat that is seeded with faecal slurry providing the indigenous gut microbiota. The model vessels are continually purged with nitrogen to maintain an anaerobic environment. The pH of each vessel is controlled to replicate that found in the proximal, medial and distal sections of the human colon, respectively, and the system is top fed with a complex growth media in keeping with the nutritional profile of the large intestine.

Faecal inoculum

Faeces from healthy volunteers with no preceding antibiotic exposure (3 months) and no CPE risk factors (no travel/no hospitalisation in high risk area), and which were negative on CPE screening [(Biomérieux chrom ID® CARBA-SMART (Carba-Smart), Cepheid Xpert® Carba-R assay (XCR) multiplex real-time PCR assay and Check-Direct CPE Screen for BD MAX™ (CD CPE) multiplex real-time PCR assay], were used in this study. Faecal samples from the volunteers were pooled to produce ~50 g of faeces, which was then mixed with 500 mL of pre-reduced PBS and filtered through muslin to produce a smooth faecal slurry (10% w/v). Identical volunteers were used for both gut model experiments.

CPE strains

Two distinct clinical isolates of carbapenemase producing *K. pneumoniae* were used in this study both supplied by Leeds Teaching Hospitals NHS Trust, a New Delhi Metallo-β-lactamase (NDM) containing strain with minimum inhibitory concentrations (MICs) of ertapenem (ERT) ≥ 32 mg/L, meropenem (MER) 8 mg/L and imipenem (IMI) 1 mg/L; and a *K. pneumoniae* carbapenemase (KPC) containing strain, with MICs of ERT 4 mg/L, IMI 8 mg/L, MER 4mg/L. Each gut model was inoculated with a different strain that had been reconstituted on blood agar from -80°C freezer storage, and

sub-cultured onto CPE selective media (Carba-Smart). The presence of carbapenemase genes was confirmed using XCR and CDCPE multiplex real-time PCR assays.

Experimental design

Two distinct gut models were used in this study to examine the behaviours of the different carbapenemase gene containing *K. pneumoniae* strains (see Figure 1). Both models were primed with faecal slurry and left without interventions for two weeks to allow bacterial populations to stabilise.

The NDM gut model was challenged with increasing inocula of *K. pneumoniae* encoding *bla*_{NDM} resistance genes. Inoculation commenced on day 15 of the experiment and continued for 8 days. The reconstituted strain was diluted in a 10-fold series to 10⁻⁷ in peptone water. Each day, 1 mL of an overnight culture (5 mL nutrient broth) of *K. pneumoniae* encoding *bla*_{NDM} was added to the model. The lowest dilution (10⁻⁷) was added on day 15 and the inocula were increased daily until a neat solution was added on day 22 of the experiment. Overnight cultures of the diluted *K. pneumoniae* encoding *bla*_{NDM} were enumerated on MacConkey agar to ensure the inocula were as expected (Supplementary material Table S1). Following the inoculation period, the model underwent a single antibiotic exposure event with imipenem. The model was dosed to achieve human in vivo gut intraluminal concentrations²⁸ using imipenem 11 mg/L three times daily for 5 days (day 41-45).

The KPC gut model was inoculated with a single inoculum of 4.9 log₁₀cfu/mL of *K. pneumoniae* encoding *bla*_{KPC} genes on day 15 of the experiment. Following inoculation, the KPC model was challenged with two separate antibiotic exposure events. Piperacillin/tazobactam (358 mg/L) was instilled between days 25-31, and meropenem (11 mg/L) between days 48-54, again dosed to simulate in vivo concentrations. Bacterial populations were monitored throughout (Figure 1) and were sampled daily for CPE and Enterobacteriaceae populations during the inoculation and

antibiotic installation periods, and sporadically thereafter. The presence/absence of carbapenemase genes was monitored via the XCR assay.




Figure 1: Schematic of experimental design. IMI-imipenem, PIP-piperacillin/tazobactam, MER-meropenem. Shapes represent time point at which isolates were sequenced. Circle denotes original strain inoculated into model, Square outline denotes plasmid uptake, triangle denotes strain with new resistance profile.

Population monitoring

Sporadic sampling of the indigenous gut populations took place before CPE inoculation. For the NDM model, twice daily sampling of CPE populations took place during the inoculation phase (day 14-21), and indigenous populations were monitored once a day. Following inoculation, both carbapenemase producing (CP) and indigenous bacterial populations were monitored daily. Both the CPE and the indigenous populations were sampled daily. Enumeration of the bacterial populations was performed by quantitative culture using Carba-Smart for CPE and MacConkey agar for indigenous populations.

These plates were read at 48 h using the appropriate dilution factor to allow enumeration in $\log_{10} \text{cfu/mL}$. For CPE populations, enumeration took place 1 h post-KPC inoculation. Fifty microliters of the diluted aliquot (up to 10^{-3}) was plated in triplicate on Carba-Smart and ESBL agars, incubated at 37°C and read at 24 h. Again, the plates were read at a factor allowing enumeration in $\log_{10} \text{cfu/mL}$. The percentage of carbapenemase producing bacteria was calculated from cfu/mL on the

149 MacConkey plate (representing total lactose fermenting (TLF) population) divided by cfu/mL on the
150 Carba-Smart plate and multiplied by 100 to give a percentage of CP bacteria in the TLF bacteria.
151 For the molecular platforms (XCR, CD CPE), 50µL of neat gut model fluid was analysed the same day,
152 in accordance with the manufacturers' instructions, except that we used gut model fluid instead of a
153 rectal swab. Please see supplementary materials for further information.

154 **Selection of CPE isolates for sequencing**

155 Three isolates were chosen from each model for sequencing.

156 From the NDM model the CP *K. pneumoniae* strain inoculated into the model, designated LCC079,
157 the CP *K. pneumoniae* strain isolated at the end of the experiment, designated LCC088, and an
158 *Escherichia coli* isolate with carbapenem resistance, designated LCC081, were sequenced.

159 From the KPC model, the original CP *K. pneumoniae* strain inoculated into the model, designated
160 LCC078, an *E. coli* isolate from the end of the experiment with carbapenem resistance, designated
161 LCC096, and a *K. pneumoniae* isolate growing on the OXA side of the CARBA-SMART plate on day 40,
162 designated LCC093, were sequenced.

163 Isolates were sequenced using Illumina technology as previously described and PacBio long-read
164 sequencing at the Icahn Institute and Department of Genetics and Genomic Sciences, Mount Sinai,
165 New York.

166 **Sequencing and genetic analysis**

167 Long read SMRT sequencing and initial de novo assembly were performed as previously described²⁹
168 using the latest P6 enzyme and chemistry and a single SMRTcell on the RSII platform. Chromosomal
169 single-nucleotide variants (SNVs) were determined by mapping Illumina reads to chromosomal
170 references for *E. coli* CFT073 (AE014075.1) or *K. pneumoniae* MGH78478 (CP000647.1), as previously
171 described³⁰. To assemble the long-read sequencing data, we initially performed hybrid assembly

using unicycler v0.4.0³¹ in bold mode with otherwise default parameters. For the KPC and OXA-232 samples, this produced complete, closed assemblies (i.e. all contigs were flagged as circular). For the NDM samples, the assemblies contained multiple un-circularised contigs, and visualisation of mapped Illumina reads indicated likely miss-assemblies. For these samples, we therefore performed a de novo long-read assembly on the PacBio subreads using HGAP3 as previously described.²⁹ Plasmid Inc typing was performed using the February 2018 version of the PlasmidFinder Enterobacteriaceae database,³² with an identity threshold of 95% and minimum length 60%. Copy number in LCC079, LCC081 and LCC088 was calculated using the unicycler assembly for LCC081, which contained *bla*_{NDM-1} on the IncFIB/IncFII plasmid described below, with a single copy of the repeat unit. For each sample, we mapped Illumina reads to a reference consisting of this plasmid structure plus the HGAP3-assembled chromosomal contig for that sample. Mapping was performed using bwa mem v0.7.12-r1039. Samtools version 1.4.1 was used to filter out supplementary alignments and calculate depth of coverage. *bla*_{NDM-1} coverage relative to the plasmid backbone was calculated as the median coverage across *bla*_{NDM-1} divided by the median coverage across the entire plasmid sequence excluding the repeat region. Similarly, the same median coverage value for the plasmid backbone was divided by the median coverage across the chromosomal contig to determine plasmid coverage relative to the chromosome. Please see supplementary materials for further information.

Results

No CPE were identified during the two-week stabilisation phase in either gut model experiment. In both models, CPE populations increased after antibiotic administration, levelling at ~5 log₁₀ cfu/mL, and persisted for the duration of the experiments, with no evidence of CPE washout.

Plate enumeration results

NDM Model

CP *K. pneumoniae* were detected after the addition of $\sim 4.9 \log_{10}$ cfu/mL (day 18); CP *K. pneumoniae* increased with increasing inocula peaking at $5-6 \log_{10}$ cfu/mL, before stabilising at $\sim 3.5 \log_{10}$ cfu/mL. Following antibiotic (imipenem) exposure, the CP *K. pneumoniae* population reduced, before expanding after administration stopped, finally accounting for $\sim 3.7\%$ of the TLF population. On day 47 of the experiment (2 days post antibiotic exposure), we began to see the emergence of a resistant CP *E. coli* population, which appeared sporadically on the CARBA-SMART agar until the end of the experiment (Figure 1).




Figure 2: NDM model. Bacterial growth on logarithmic scale. Solid arrow-inoculation phase, open arrow-antibiotic instillation, NDM-Klebsiella pneumoniae with bla_{NDM} , IMI-imipenem. Black line - total lactose fermenting population, grey line-carbapenemase producing *K. pneumoniae*. % refers to resistant proportion of total Enterobacteriaceae. ● -LCC079, ▲ -LCC081, ★ -LCC088

KPC Model

Post-inoculation, CP *K. pneumoniae* counts were $\sim 1-2 \log_{10}$ cfu/mL, accounting for $<0.01\%$ of the TLF population. Dosing with piperacillin/tazobactam resulted in an increase of $>8 \log_{10}$ cfu/mL in CP *K. pneumoniae* populations, which comprised $\sim 25\%$ of TLF population after dosing stopped. On day 35 of the experiment (20 days post CP *K. pneumoniae* inoculation and 5 days post end of antibiotic administration), a CP *E. coli* emerged, peaking at $5.5 \log_{10}$ cfu/mL on day 45. Following a second antibiotic exposure with meropenem, there were further increases in carbapenemase-producing

populations at day 65 (end of the experiment), comprising both the CP *K. pneumoniae* and CP *E. coli* populations, which combined accounted for ~45% of the TLF population.




Figure 3: KPC model. Bacterial growth on logarithmic scale. Solid arrow-inoculation phase, open arrow-antibiotic instillation KPC-Klebsiella pneumoniae with bla_{KPC}, PIP-piperacillin/tazobactam, MER-meropenem. Black line-total lactose fermenting population, grey line-carbapenemase producing *K. pneumoniae*. % refers to resistant proportion of total Enterobacteriaceae. ● -LCC078, ★LCC093 - -LCC096

Long read sequencing

Table one presents a summary of each bacterial isolate and its characteristics.

Model	Collection number	Day	Isolate	Subtype	Plasmid encoding carbapenemase
NDM	LCC079	15	<i>K. pneumoniae</i>	ST147	IncFIB/IncFII
	LCC088	57	<i>K. pneumoniae</i>	ST147	IncFIB/IncFII
	LCC081	48	<i>E. coli</i>	ST88	IncFIB/IncFII
KPC	LCC078	15	<i>K. pneumoniae</i>	ST661	pKpQIL-D2
	LCC096	57	<i>E. coli</i>	ST357	pKpQIL-D2
	LCC093	40	<i>K. pneumoniae</i>	ST14	ColKP3

--	--	--	--	--	--

Table 1: Summary of bacterial isolates characteristics

NDM Model

LCC079 (*K. pneumoniae*, single-locus variant of ST147, original strain) and LCC088 (*K. pneumoniae*, same single-locus variant of ST147, isolated at the end of the experiment) differed by only one chromosomal SNV, indicating that the original inoculated strain was maintained throughout the experiment. For both these isolates, as well as LCC081 (the CP *E. coli* ST88 isolated on day 47), the *bla*_{NDM-1} gene was located on the same plasmid backbone, indicating *bla*_{NDM-1} plasmid transfer from *K. pneumoniae* to *E. coli* during the experiment. This plasmid represents a previously undescribed >170 kb IncFIB/IncFII plasmid. Within this plasmid, the *bla*_{NDM-1} gene was located within a 6,893 bp region flanked by 1,695 bp direct repeats. There was evidence that the 6,893 bp + 1,695 bp structure was tandemly repeated: however, the exact number of repeat units in each case could not be ascertained from the long-read data, and Illumina coverage suggested variation in the number of repeat units between the three isolates (Table 2).

The same *bla*_{NDM-1}-containing repeat structure has previously been described in the unrelated IncHI1B/IncFIB plasmid pPMK1-NDM from a *K. pneumoniae* isolated in Nepal in 2011.³³ There was no evidence for any other shared plasmids between the *K. pneumoniae* and *E. coli* isolates.

Sample	<i>bla</i> _{NDM-1} coverage relative to plasmid backbone	Plasmid coverage relative to chromosome
LCC079	2.7	1.7
LCC081	1.6	0.9
LCC088	2.3	1.8

Table 2: Estimated genomic coverage of tandem repeat.

KPC model

LCC078 (*K. pneumoniae* ST661, original strain) and LCC096 (*E. coli* ST357, isolated on day 57) both contained *bla*_{KPC-2} on an identical 111,742 bp IncFII/IncR plasmid with >99% sequence identity to pKpQIL-D2⁵, indicating *bla*_{KPC} plasmid transfer from *K. pneumoniae* to *E. coli* during the experiment. There were no other shared plasmids between these two isolates; LCC078 additionally contained a 249,604 bp IncFIB plasmid, a 4,350 bp non-typeable plasmid and a 4,000 bp Col440I plasmid, and LCC096 additionally contained a 148,387 bp IncFIB/IncFIC plasmid and a 3,904 bp Col156 plasmid. LCC093 (*K. pneumoniae* ST14, taken on day 40) contained *bla*_{OXA-232} on a 6,141 bp ColKP3 plasmid, which was identical to a previously described *bla*_{OXA-232} plasmid from a *K. pneumoniae* ST14 isolated in the US in 2013.³⁴ LCC093 additionally contained a 273,971 bp IncHI1B/IncFIB plasmid, a 211,819 bp IncFII/IncFIB plasmid, a 4,167 bp non-typeable plasmid and a 2,095 bp non-typeable plasmid.

Discussion

The *in-vitro* human gut model provides a unique insight into CPE colonisation dynamics in the colon, allowing biomass enumeration of the microbiota in real time. We note that in the forerunner of our gut model microbiota composition was validated against the colonic bacteria found in sudden road traffic accident victims³⁵. Our model has since been used extensively to successfully predict the behaviour of antibiotics in the context of *Clostridium difficile* infection, which is clearly mediated via alterations to the gut microbiota.³⁶ Utilising our predictive model, we can follow changes that occur in both resistant and susceptible bacterial populations and count viable bacterial populations with carbapenem resistance genes. The additional long read sequencing data enabled us to track the ancestral strains/plasmids as they disseminated within the simulated colon.

We chose to study *bla*_{KPC} and *bla*_{NDM} as these strains represent two of the 'big five' carbapenemases present worldwide and are frequently encountered in clinical practice and hence freely available for study. In the NDM model, increasing inocula were added over 7 days to determine the threshold at

which all screening tests (in triplicate) became positive. We then used our data to determine the inoculum size for the KPC model, and so used a single exposure event to replicate what we believe is most likely to occur in clinical practice. The selected antibiotics represent those commonly used in clinical practice; the regimen of piperacillin/tazobactam followed by meropenem was utilised to represent an often employed escalation of antibiotic treatment in patients who have failed to respond to initial empirical (piperacillin/tazobactam) antibiotic therapy.

Within the NDM model, the use of increasing daily inocula demonstrated that at low levels (<4.9 log₁₀cfu/mL) commonly used screening methods did not detect CPE. This is a phenomenon that we have observed before and is not unique to the NDM strain (unpublished data, Rooney CM, Davies K, Wilcox MH, Chilton CH. HCAI research group, Leeds). For, the increasing inocula (NDM model) and the single inoculum (KPC model), the resistant populations stabilised before antibiotic exposure, suggesting that antibiotic induced dysbiosis not a prerequisite for CPE gut colonisation. However, after antibiotic dosing, selective pressure led to a marked increase in both CPE strains. Current understanding^{4, 6-8} suggests that antibiotic exposure is a risk factor for CPE colonisation, which is in keeping with our findings. Nonetheless, if antibiotic selective pressure is driving already present resistant populations into a detectable range, then true colonisation rates could be far higher than reported.

Adding further weight to this argument, in the KPC model we identified on day 40 a *K. pneumoniae* strain that carried *bla*_{OXA232} resistance genes, an isolate we had neither inoculated into the model nor detected on screening. This isolate was only detected after antibiotic exposure and was present at very low levels (sporadic colonies). Interestingly, the plasmid encoding the *bla*_{OXA232} has been previously described³⁴ in a US strain carrying dual carbapenem resistance genes (NDM+ OXA), although sequencing of our strain did not show both these resistance mechanisms. We hypothesize that this isolate was undetectable until clonal expansion of the population occurred under antibiotic selective pressure. We acknowledge that environmental contamination or presence of CPE in donor

samples are possible alternative explanations for our results; however, these scenarios are unlikely given that no *bla*_{OXA232} resistant strains were used in the laboratory at the time of this experiment, and this was not observed in the NDM model (which was primed with faeces from the same donor as used in the KPC model).

In the NDM model, we have shown that the viable resistant population doubled after antibiotic exposure; combining these results and the long read sequencing data, we have demonstrated that this was due to an expanding clonal population. This provides clear evidence that the biomass of resistant bacteria and the subsequent transmission risk is greatest after antibiotic selective pressure. We also identified the emergence of an *E. coli* population with newly acquired carbapenem resistance, similarly to the KPC model. Again, as in the KPC model, in the NDM model this population shared the same plasmid as the inoculated strain, providing evidence that horizontal gene transfer had taken place, promoted by antibiotic exposure, from the dominant clonal population to susceptible bacterial populations, as hypothesised in vivo.³⁷ Factors influencing conjugation rate include temperature, substrate, plasmid content, and donor and recipient strain identity.³⁸ Many of these parameters are tightly controlled in our gut model that simulates the human colonic habitat. Others have shown biofilm formation provides the optimal surroundings for horizontal gene transfer to take place;³⁹ we intend to explore such possibilities in future CPE gut model experiments, but note that biofilm does form on the inner surfaces of vessels (although this was not specifically sampled in these studies).

The KPC model had a much higher CPE biomass than the NDM model, despite greater total inocula in the NDM model. This is true for both the inoculated strain LCC078 and the newly resistant *E. coli* population LCC096 when compared to LCC079 and LCC081, respectively (Figure 2-3), potentially related to the different antibiotics used (piperacillin/tazobactam vs imipenem respectively) and their impact on other faecal flora. We hypothesise that at a higher biomass burden within the gut we would observe an increased frequency of horizontal gene transfer events. However, the exact

number of such events would be difficult to determine given concomitant vertical transmission. We caution, nevertheless, that the CPE biomass between gut models may not be directly comparable. Although the same donors have been used to increase reproducibility between models, piperacillin/tazobactam dosing in the KPC model resulted in a significant increase in the CP *K. pneumoniae* population (Figure 3), more so than imipenem exposure in the NDM model (Figure 2) (reflecting the relatively low imipenem MIC of LCC079). Therefore the higher biomass of CP *K. pneumoniae* in the KPC model is reliant on both strain characteristics and antibiotic exposure. This highlights the fact that antimicrobial stewardship is crucial to containing a CPE outbreak as inappropriate antibiotic prescribing may lead to large clonal expansion within the gut, leading to higher biomass, frequent horizontal transfer events and subsequent spread of carbapenemase producing organisms within the ward environment. Given that we were unable to detect low-level CPE colonisation within the NDM gut model even when inoculating known quantities, and that extended spectrum antibiotics are highly selective for carbapenemase producers, we advocate strict antimicrobial stewardship policies for all patients in a ward/unit environment during a period of a CPE outbreak. Slow implementation or lack of such an intervention might explain why some outbreaks expand and persist, and potentially lead to endemicity in some cases.

Conclusion

We have used an in vitro human gut model to investigate the possible outcomes of CPE exposure leading to CPE colonisation. Under antibiotic selective pressure, we have demonstrated clonal expansion and, critically resistance gene transfer between species, within healthy human gut microbiota. Furthermore, previously unidentified, resistant populations were found. This study provides important data regarding CPE colonisation and dissemination within the gut microbiota, which may have key implications for antibiotic prescribing following introduction of CPE into a clinical setting and/or a CPE outbreak.

Acknowledgements

Funding

This work was support by the National Institute for Health Research Health, Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE). CMR was supported by the NIHR ACF scheme. ASW and DWC are supported by the Oxford NIHR Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, the Department of Health or PHE.

NIHR Health Protection Research Unit Steering Committee: J Coia, N French, C Marwick, M Sharland

Transparency declarations

MHW has received consulting fees from Abbott Laboratories, Actelion, Antabio, AiCuris, Astellas, Astra-Zeneca, Bayer, Biomérieux, Cambimune, Cerexa, Da Volterra, The European Tissue Symposium, Ferring, The Medicines Company, Menarini, Merck, Meridian, Motif Biosciences, Nabriva, Paratek, Pfizer, Qiagen, Roche, Seres, Spero, Surface Skins, Sanofi-Pasteur, Seres, Summit, Synthetic Biologics and Valneva; lecture fees from Abbott, Alere, Allergan, Astellas, Astra-Zeneca, Merck, Nabriva, Pfizer, Roche & Seres; grant support from Abbott, Actelion, Astellas, Biomérieux, Cubist, Da Volterra, Merck, MicroPharm, Morphochem AG, Motif Biosciences, Nabriva, Paratek, Pfizer, Sanofi-Pasteur, Seres, Summit and The European Tissue Symposium. CHC has received research funding from Da Volterra, Paratek Plc, Actavis, Teva Pharmaceuticals USA Inc, Astellas Pharma Europe Ltd, Cubist Pharmaceuticals, Seres Therapeutics and has received honorarium from Astellas Pharma Europe Ltd.

References

1. Glasner C, Albiger B, Buist G et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. *Euro Surveill* 2013; **18**.
2. Findlay J, Hopkins KL, Alvarez-Buylla A et al. Characterization of carbapenemase-producing Enterobacteriaceae in the West Midlands region of England: 2007-14. *J Antimicrob Chemother* 2017; **72**: 1054-62.
3. Woodford N, Zhang J, Warner M et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. *J Antimicrob Chemother* 2008; **62**: 1261-4.
4. Poole K, George R, Decraene V et al. Active case finding for carbapenemase-producing Enterobacteriaceae in a teaching hospital: prevalence and risk factors for colonization. *J Hosp Infect* 2016; **94**: 125-9.
5. Doumith M, Findlay J, Hirani H et al. Major role of pKpQIL-like plasmids in the early dissemination of KPC-type carbapenemases in the UK. *J Antimicrob Chemother* 2017; **72**: 2241-8.
6. Hilliquin D, Le Guern R, Thepot Seegers V et al. Risk factors for acquisition of OXA-48-producing Klebsiella pneumonia among contact patients: a multicentre study. *J Hosp Infect* 2018; **98**: 253-9.

7. Ben-David D, Masarwa S, Navon-Venezia S et al. Carbapenem-resistant *Klebsiella pneumoniae* in post-acute-care facilities in Israel. *Infect Control Hosp Epidemiol* 2011; **32**: 845-53.
8. Borer A, Saidel-Odes L, Eskira S et al. Risk factors for developing clinical infection with carbapenem-resistant *Klebsiella pneumoniae* in hospital patients initially only colonized with carbapenem-resistant *K pneumoniae*. *Am J Infect Control* 2012; **40**: 421-5.
9. Patel G, Huprikar S, Factor SH et al. Outcomes of carbapenem-resistant *Klebsiella pneumoniae* infection and the impact of antimicrobial and adjunctive therapies. *Infect Control Hosp Epidemiol* 2008; **29**: 1099-106.
10. Schwaber MJ, Lev B, Israeli A et al. Containment of a country-wide outbreak of carbapenem-resistant *Klebsiella pneumoniae* in Israeli hospitals via a nationally implemented intervention. *Clin Infect Dis* 2011; **52**: 848-55.
11. Lepelletier D, Berthelot P, Lucet JC et al. French recommendations for the prevention of 'emerging extensively drug-resistant bacteria' (eXDR) cross-transmission. *J Hosp Infect* 2015; **90**: 186-95.
12. Martin J, Phan HTT, Findlay J et al. Covert dissemination of carbapenemase-producing *Klebsiella pneumoniae* (KPC) in a successfully controlled outbreak: long- and short-read whole-genome sequencing demonstrate multiple genetic modes of transmission. *J Antimicrob Chemother* 2017; **72**: 3025-34.
13. Manikal VM, Landman D, Saurina G et al. Endemic carbapenem-resistant *Acinetobacter* species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. *Clin Infect Dis* 2000; **31**: 101-6.
14. Semin-Pelletier B, Cazet L, Bourigault C et al. Challenges of controlling a large outbreak of OXA-48 carbapenemase-producing *Klebsiella pneumoniae* in a French university hospital. *J Hosp Infect* 2015; **89**: 248-53.
15. Cerqueira GC, Earl AM, Ernst CM et al. Multi-institute analysis of carbapenem resistance reveals remarkable diversity, unexplained mechanisms, and limited clonal outbreaks. *Proc Natl Acad Sci USA* 2017; **114**: 1135-40.
16. Sheppard AE, Stoesser N, Wilson DJ et al. Nested Russian Doll-Like Genetic Mobility Drives Rapid Dissemination of the Carbapenem Resistance Gene blaKPC. *Antimicrob Agents Chemother* 2016; **60**: 3767-78.
17. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. *Virulence* 2017; **8**: 460-9.
18. Codjoe FS, Donkor ES. Carbapenem Resistance: A Review. *Medical Sciences* 2018; **6**: 1.
19. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2001; **45**: 1151-61.
20. Kitchel B, Sundin DR, Patel JB. Regional dissemination of KPC-producing *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2009; **53**: 4511-3.
21. Ikonomidis A, Tokatlidou D, Kristo I et al. Outbreaks in distinct regions due to a single *Klebsiella pneumoniae* clone carrying a bla VIM-1 metallo- β -lactamase gene. *J Clin Microbiol* 2005; **43**: 5344-7.
22. Carrer A, Poirel L, Eraksoy H et al. Spread of OXA-48-positive carbapenem-resistant *Klebsiella pneumoniae* isolates in Istanbul, Turkey. *Antimicrob Agents Chemother* 2008; **52**: 2950-4.
23. Thomas CP, Moore LS, Elamin N et al. Early (2008-2010) hospital outbreak of *Klebsiella pneumoniae* producing OXA-48 carbapenemase in the UK. *Int J Antimicrob Agents* 2013; **42**: 531-6.
24. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. *Emerg Infect Dis* 2011; **17**: 1791-8.
25. Best EL, Freeman J, Wilcox MH. Models for the study of *Clostridium difficile* infection. *Gut Microbes* 2012; **3**: 145-67.

26. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon *Clostridium difficile* proliferation and toxin production in a triple-stage chemostat model of the human gut. *J Antimicrob Chemother* 2003; **52**: 96-102.
27. Chilton CH, Crowther GS, Baines SD et al. In vitro activity of cadazolid against clinically relevant *Clostridium difficile* isolates and in an in vitro gut model of *C. difficile* infection. *J Antimicrob Chemother* 2014; **69**: 697-705.
28. Mayer M, Tophof C, Opferkuch W. Bile levels of imipenem in patients with t-drain following the administration of Imipenem/Cilastatin. *Infection* 1988; **16**: 225-8.
29. Mathers AJ, Stoesser N, Sheppard AE et al. *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* at a single institution: insights into endemicity from whole-genome sequencing. *Antimicrob Agents Chemother* 2015; **59**: 1656-63.
30. Stoesser N, Sheppard AE, Peirano G et al. Genomic epidemiology of global *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Escherichia coli*. *Sci Rep* 2017; **7**: 5917.
31. Wick RR, Judd LM, Gorrie CL et al. Unicycler: Resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput Biol* 2017; **13**: e1005595.
32. Carattoli A, Zankari E, Garcia-Fernandez A et al. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 2014; **58**: 3895-903.
33. Stoesser N, Giess A, Batty EM et al. Genome sequencing of an extended series of NDM-producing *Klebsiella pneumoniae* isolates from neonatal infections in a Nepali hospital characterizes the extent of community- versus hospital-associated transmission in an endemic setting. *Antimicrob Agents Chemother* 2014; **58**: 7347-57.
34. Doi Y, Hazen TH, Boitano M et al. Whole-genome assembly of *Klebsiella pneumoniae* coproducing NDM-1 and OXA-232 carbapenemases using single-molecule, real-time sequencing. *Antimicrob Agents Chemother* 2014; **58**: 5947-53.
35. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a Three-Stage Compound Continuous Culture System for Investigating the Effect of Retention Time on the Ecology and Metabolism of Bacteria in the Human Colon. *Microb Ecol* 1998; **35**: 180-7.
36. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on *Clostridium difficile* growth and toxin production in a human gut model. *J Antimicrob Chemother* 2005; **55**: 974-82.
37. Borgia S, Lastovetska O, Richardson D et al. Outbreak of carbapenem-resistant enterobacteriaceae containing blaNDM-1, Ontario, Canada. *Clin Infect Dis* 2012; **55**: e109-17.
38. Hardiman CA, Weingarten RA, Conlan S et al. Horizontal Transfer of Carbapenemase-Encoding Plasmids and Comparison with Hospital Epidemiology Data. *Antimicrob Agents Chemother* 2016; **60**: 4910-9.
39. Madsen JS, Burmolle M, Hansen LH et al. The interconnection between biofilm formation and horizontal gene transfer. *FEMS Immunol Med Microbiol* 2012; **65**: 183-95.